Royalty Pharma PLC (RPRX) — 10-Q Filings

All 10-Q filings from Royalty Pharma PLC. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Royalty Pharma's Q3 Net Income Dips Amid Soaring R&D, G&A Costs — Nov 5, 2025 Risk: medium
Royalty Pharma plc (RPRX) reported a consolidated net income of $968.279 million for the nine months ended September 30, 2025, a decrease from $996.462 million
Royalty Pharma's Q2 Royalties Surge 27% to $1.25B — Aug 6, 2025 Risk: medium
Royalty Pharma plc reported strong financial performance for the six months ended June 30, 2025, with total royalty receipts from financial royalty assets reach
Royalty Pharma plc Files Q1 2025 10-Q — May 8, 2025 Risk: low
Royalty Pharma plc filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter o
Royalty Pharma Q3 Revenue Rises to $644M — Nov 6, 2024 Risk: low
Royalty Pharma plc filed its 10-Q for the period ending September 30, 2024. The company's financial royalty assets generated $644 million in the third quarter o
Royalty Pharma plc Files Q2 2024 10-Q — Aug 8, 2024 Risk: low
Royalty Pharma plc filed its 10-Q for the period ending June 30, 2024. The company's financial statements and disclosures for the second quarter and first half
Royalty Pharma plc Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: low
Royalty Pharma plc (RPRX) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Royalty Pharma plc filed its quarterly report (10-Q) on May 9, 2024, for

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX